Approximately one in every 500 African-American births has sickle cell disease. The disease is also common among Hispanic and Mediterranean-American people Sickle cell disease is a genetic disorder. However, it is not always clear whether or not a child will develop the disease. Sickle cell disease Symptoms are usually noticeable during pregnancy or shortly after birth. The North America Sickle Cell Disease Market is growing rapidly. Various factors are expected to drive the market growth, including increasing prevalence of the disease, growing government initiatives, and a focus on rare diseases.
Treatment for sickle cell disease is available, depending on the symptoms the patient experiences. However, studies indicate that only one out of four patients with the disease receives standard care. This is due in large part to the fact that most patients don’t receive pain management early enough. This means that a person with sickle cell disease should consider a sibling donor before undergoing a transplant. A blood test or cheek swab will reveal if the sibling is a compatible donor. Thanks to growing investments and the demand for better treatments, the North America Sickle Cell Disease Market is expanding at fast rate.
Latest report available at Coherent Market Insights indicates that North America Sickle Cell Disease Market to Surpass US$ 2,200.5 Million by 2028
Normal red blood cells are soft and disk-shaped. They can easily move through blood vessels. In contrast, sickle cell hemoglobin is stiff and sticky and often forms into a sickle shape when losing oxygen. If this happens, the blood flow will be disrupted and can result in painful episodes. And in extreme cases, the affected person may even die. Aside from being tired, people with sickle cell disease may have difficulty breathing or even moving around. A severe complication of this disease is pulmonary hypertension. This condition causes high blood pressure in the arteries supplying the lungs. It can lead to heart failure or stroke. It is estimated that about 10 percent of adults with the disease develop it. In December 2021, the U.S. Food and Drug Administration (FDA) granted approval to Oxbryta (voxelotor) tablets for treating sickle cell disease in pediatric patients aging 4 to 11 years.